作者投稿
专家审稿
编辑办公
邮件订阅
RSS
Classification and Coding for Coronavirus Disease 2019 by International Classification ofDiseases: Updates and Interpretation
-
摘要: 在全球新型冠状病毒肺炎(coronavirus disease 2019，COVID-19)疫情大流行背景下，使用特定的国际疾病分类(international classification of diseases，ICD)编码将有助于对COVID-19相关情况开展标准化收集、分类和统计，有利于快速寻找疾病诊治规律、及时掌握流行变化趋势并评估预防治疗效果。本文对世界卫生组织最新发布的ICD-10及ICD-11中COVID-19相关分类标准进行梳理和解读，旨在为完善和丰富我国本土化的COVID-19相关ICD编码标准提供参考。Abstract: In the context of coronavirus disease 2019 (COVID-19), the leverage of specific codes of international classification of diseases(ICD) will substantially help standardize the process of data collection, classification and statistics of COVID-19-related conditions, thus facilitating the rapid research and development of diagnosis and treatment, dynamic monitoring of epidemic trend, as well as effectiveness evaluation of preventive and therapeutic measures taken in the fight against COVID-19. This review summarized and interpreted the latest ICD-10 and ICD-11 classification standards of COVID-19 related conditions and aimed to provide reference to improve and enrich the localized application of ICD coding standards for COVID-19 related conditions in China.作者贡献: 周婧雅负责收集资料，撰写文章; 范俊平、张萌负责修订文章; 周炯负责审校文章。利益冲突: 无
-
ICD-10分类与编码 ICD-11分类与编码 分类名称 编码 分类名称 编码 COVID-19，病毒已证实 U07.1 COVID-19，病毒已证实 RA01.0 COVID-19，病毒未证实 U07.2 COVID-19，病毒未证实 RA01.1 其他可疑疾病或情况的观察 Z03.8 其他可疑疾病或情况的医学观察和评估，排除感染SARS-CoV-2 QA02.Y & XN109 COVID-19个人史 U08 COVID-19个人史 QC42.0 病毒已证实的COVID-19个人史 QC42.0/RA01.0 病毒未证实的COVID-19个人史 QC42.0/RA01.1 COVID-19转归后的情况 U09+特定情况 COVID-19转归后的情况 RA02+特定情况 COVID-19相关多系统炎症综合征 U10 COVID-19相关多系统炎症综合征 RA03 其他病毒性疾病的特殊筛查 Z11.5 特指对感染SARS-CoV-2的筛查 QA08.5 & XN109 为抗COVID-19采取必要的免疫 U11 为抗COVID-19采取必要的免疫 QC01.9 COVID-19疫苗使用过程中的不良反应，未特指 不良反应编码+U12 在治疗过程中与药物、药剂或生物制品有关的损伤或伤害，与COVID-19疫苗有关 不良反应编码/PL00 & XM68M6# COVID-19：新型冠状病毒肺炎; ICD：国际疾病分类; SARS-CoV-2:新型冠状病毒; #扩展编码可根据具体疫苗种类更改 
下载: 导出CSV
-
[1] 世界卫生组织. 疾病和有关健康问题的国际统计分类第十次修订本第二卷(第二版)[M]. 北京: 人民卫生出版社, 2010: 2-3. [2] 国家卫生健康委员会, 国家医疗保障局. 关于印发新型冠状病毒感染相关ICD代码的通知[EB/OL]. (2021-02-13). [2021-02-16]. http://www.nhc.gov.cn/xcs/zhengcwj/202002/dcf3333b740f4fabad5f9f908d1fc5b4.shtml. [3] World Health Organization. ICD-10 Version: 2019[EB/OL]. (2021-01-25). [2021-02-24]. https://icd.who.int/browse10/2019/en#/. [4] World Health Organization. ICD-11 for Mortality and Morbidity Statistics[EB/OL]. (2021-09-17). [2021-02-24]. https://icd.who.int/browse11/l-m/en#/. [5] World Health Organization. ICD-11 Maintenance Platform, ICD-11 Mortality and Morbidity Statistics[EB/OL]. (2021-04-11). [2021-04-11]. https://icd.who.int/dev11/l-m/en. [6] World Health Organization. COVID-19 Clinical management Living guidance[EB/OL]. (2021-01-25). [2021-02-20]. https://apps.who.int/iris/bitstream/handle/10665/338882/WHO-2019-nCoV-clinical-2021.1-eng.pdf?sequence=1&isAllowed=y. [7] World Health Organization. ICD-10 Version: 2016[EB/OL]. (2016-09-01). [2021-02-20]. https://icd.who.int/browse10/2016/en#/. [8] 国家卫生健康委员会, 国家中医药管理局. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第八版)的通知[EB/OL]. (2021-08-19). [2021-02-20]. http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml. [9] 国家卫生健康委员会, 国家中医药管理局. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第五版)的通知[EB/OL]. (2021-02-04). [2021-02-20]. http://www.gov.cn/zhengce/zhengceku/2021-02/05/content_5474791.htm. [10] Jaffri A, Jaffri UA. Post-Intensive care syndrome and COVID-19: crisis after a crisis?[J]Heart Lung, 2020, 49: 883-884. doi: 10.1016/j.hrtlng.2020.06.006 [11] Huang CL, Huang L, Wang YM, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study[J]. Lancet, 2021, 397: 220-232. doi: 10.1016/S0140-6736(20)32656-8 [12] Carfi A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19[J]. JAMA, 2020, 324: 603-605. doi: 10.1001/jama.2020.12603 [13] Jiang L, Tang K, Levin M, et al. COVID-19 and multisy-stem inflammatory syndrome in children and adolescents[J]. Lancet Infect Dis, 2020, 20: e276-e288. doi: 10.1016/S1473-3099(20)30651-4 [14] Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents[J]. N Engl J Med, 2020, 383: 334-346. doi: 10.1056/NEJMoa2021680 [15] Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort[J]. Ann Rheum Dis, 2020, 79: 999-1006. http://ard.bmj.com/content/early/2020/08/05/annrheumdis-2020-218614 [16] Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State[J]. N Engl J Med, 2020, 383: 347-358. doi: 10.1056/NEJMoa2021756 [17] Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study[J]. Lancet, 2020, 395: 1771-1778. doi: 10.1016/S0140-6736(20)31103-X [18] Consiglio CR, Cotugno N, Sardh F, et al. The Immuno-logy of Multisystem Inflammatory Syndrome in Children with COVID-19[J]. Cell, 2020, 183: 968-981. doi: 10.1016/j.cell.2020.09.016 [19] World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19[EB/OL]. (2021-05-15). [2021-2-24]. https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19. -
点击查看大图
表(2)
计量
- 文章访问数: 564
- HTML全文浏览量: 76
- PDF下载量: 48
- 被引次数: 0
